• Psoriasis
  • Symptoms & Diagnosis
  • Types
  • Locations
  • Triggers
  • Psoriasis Treatments

  

  • Accessing Health Care
  • Resources and Tools
• Psoriatic Arthritis
  • Symptoms & Diagnosis
  • Types
  • Treatments

  

  • Accessing Health Care
  • Resources and Tools
• Research
  • Research Priorities

  • NPF-Funded Research
  • Victor Henschel BioBank
  • Science of Psoriatic Diseases

  • For Researchers

  Location:	Any Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachussetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming
  Condition:	Psoriasis Psoriatic Arthritis

• Advocacy
  • Policy Priorities
  • Take Action
  • Advocacy News and Events

  • For Policy Makers
• In Your Area
  

  • Events and Programs
  • Calendar of Events
  • Walk to Cure Psoriasis
• Get Involved
  • Walk to Cure Psoriasis
  • Donate
  • Advocate
  • Volunteer
  • Special Events
  • Calendar of Events
• Donate
  

  • Ways to Give
  • Become a Member
  • Support Research
  • Remember NPF in Your Will
  • Fundraising Events
  • Give Stock
  • Tribute and Memorial Gifts
  • Become a Professional Member

Biologic Drugs: Fact Sheets

Enbrel (etanercept)

• FDA-approved for treating psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis and ankylosing spondylitis
• Patients give themselves an injection once or twice a week
• Taken continuously to maintain results
• May reduce the progression of joint damage
• Occasional blood tests are recommended

Humira (adalimumab)

• FDA-approved for treating psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis
• Individuals give themselves an injection usually every other week
• Patients should be screened for latent (hidden) tuberculosis (TB) before taking Humira
• May reduce the progression of joint damage
• Occasional blood tests are recommended

      If you take Humira and recently received a letter from United Healthcare indicating they will no longer
      provide coverage, call 1.800.4.HUMIRA (448.6472) to discuss how to obtain or continue co-pay
      assistance. Learn

Remicade (infliximab)

• FDA-approved for psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis and Crohn’s disease
• Given by three infusions in a doctor’s office during the first six weeks of treatment
• Later infusions repeated every eight weeks
• Patients should be screened for latent (hidden) tuberculosis (TB) before taking infliximab
• May reduce the progression of joint damage
• Blood tests are recommended on a regular basis

Simponi (golimumab)

• FDA-approved for psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis
• Patients give themselves an injection one time per month
• Patients should be screened for latent (hidden) tuberculosis (TB) before taking
• May reduce the progression of joint damage
• Blood tests are recommended on a regular basis

Stelara (ustekinumab)

• FDA-approved for plaque psoriasis
• After two initial doses at weeks 0 and 4, patients receive an injection by a health care provider once every 12 weeks
• Patients should be screened for latent (hidden) tuberculosis (TB) before taking Stelara
• Occasional blood tests are recommended